Peer-Reviewed Publications on Stellest
Peer-Reviewed Stellest Studies (Summary List)
Several studies have been published in respected vision science journals. While we do not list every detail here, the key papers examine Stellest performance over one to three years in children. These studies measured eyeglass prescription changes and eye growth compared to standard single-vision lenses.
- Randomized controlled trials enrolling children aged eight to thirteen with low to moderate myopia at baseline
- Studies conducted in multiple countries with follow-up periods ranging from one to three years
- Primary endpoints include changes in spherical equivalent refraction and axial length measured with cycloplegia and optical biometry
- Safety and quality-of-life assessments reported at regular intervals throughout the trials
- Results published in peer-reviewed optometry and ophthalmology journals following independent scientific review
Understanding the Research Behind Stellest Lenses
Peer-reviewed studies are research projects that independent scientists evaluate before publication. This process ensures the methods are sound and the conclusions are supported by data. For Stellest lenses, published trials show measurable effects in slowing how quickly nearsightedness worsens in children.
The journals that publish these studies require strict standards for design, measurement, and reporting. When we discuss Stellest with you, we rely on these validated findings rather than marketing claims alone. This approach gives you and your child trustworthy information, though we also acknowledge areas where evidence is still emerging.
Evidence-based care means we choose treatments proven to work in real clinical settings. For a condition that affects your child for years, you want more than guesswork. Published research on Stellest provides data we use to predict outcomes and set realistic expectations.
When high-quality studies show consistent results, we can discuss risks and benefits with you more clearly. This transparency helps you make informed decisions about whether Stellest is right for your family. We also talk openly about what remains uncertain so you can weigh all factors.
Several peer-reviewed papers have examined how Stellest lenses perform over one to three years of wear. These studies include hundreds of children across different countries and age groups. Researchers have measured not only eyeglass prescription changes but also the physical growth of the eye itself.
Current publications focus on children who wear Stellest full-time during waking hours. The trials compare results to children wearing standard single-vision lenses. This head-to-head approach lets scientists calculate how much extra benefit Stellest provides.
Key Findings from Clinical Trials
Published studies report that children wearing Stellest lenses experience slower myopia progression compared to those in standard glasses. On average, trials show a reduction in the rate of prescription change and eye elongation. These benefits appear most pronounced in the first year of wear, though effects persist with continued use.
Researchers measure effectiveness by tracking both the prescription strength needed for clear vision and the axial length of the eye. Slowing axial elongation is especially important because it may reduce the risk of eye health problems later in life. We use these published benchmarks when we monitor your child's progress.
Most peer-reviewed Stellest trials have enrolled children between the ages of eight and thirteen. Within this range, the lenses appear to work across the entire age spectrum. Younger children in the studies showed similar response patterns to older participants.
- Eight to ten year-olds demonstrated measurable slowing of myopia in published trials
- Eleven to thirteen year-olds also benefited, though progression rates naturally vary by age
- Researchers continue to study whether effects extend to teenagers and younger children
- Starting treatment earlier may maximize total benefit over the years of active myopia progression
Long-term data published so far extend up to about three years. Available published follow-up suggests the effect is sustained with consistent wear, though longer-term durability and outcomes after stopping lens wear are still being studied. We do not yet have decades of data to confirm what happens as children grow into adulthood.
Published data are limited on what happens after discontinuation, including whether progression returns to baseline rates. If treatment is stopped, we monitor closely and adjust the plan based on measured progression. Some trials report wear-time data from questionnaires or diaries, confirming that children who wear Stellest for more hours each day tend to have better outcomes. This finding underscores the importance of daily compliance. We discuss realistic wear schedules with families to help maximize the treatment effect.
Clinical trials use standard single-vision lenses as the control group. Children receiving traditional glasses continue to progress at typical rates. Those assigned to Stellest show statistically significant reductions in both prescription change and axial elongation.
The published differences indicate slower progression, with estimates varying depending on the study, the specific outcome measured (spherical equivalent versus axial length), and the time point. These numbers help us set expectations when we recommend Stellest. Your child will likely still experience some myopia increase, but at a reduced pace compared to doing nothing special.
How Researchers Studied Stellest
Most published Stellest trials are randomized controlled studies. This means children are assigned by chance to either Stellest or standard lenses, and neither the researchers nor the families choose which group they join. Random assignment reduces bias and makes the findings more reliable. Many spectacle-lens trials use masking, meaning participants or examiners do not know which lens type is worn, which further reduces expectation bias and strengthens the reliability of subjective outcomes like comfort and satisfaction.
Participants typically needed to have a certain level of myopia at enrollment and no other major eye conditions. Children with significant strabismus, amblyopia, or ocular pathology are often excluded, which can limit how directly results apply to those groups. Researchers also screened for general health and ability to wear glasses full-time. These criteria help ensure that results apply to children similar to those in the studies.
Published trials use standardized instruments to measure refractive error and axial length. Because children can accommodate during testing, high-quality studies usually include cycloplegia when measuring refractive error. Refractive error tells us the eyeglass prescription strength, while axial length measures the front-to-back size of the eye. Both metrics are objective and reproducible.
- Trials typically use cycloplegic refraction, often cycloplegic autorefraction, to reduce accommodation-related error in children
- Optical biometers measure axial length with precision down to fractions of a millimeter
- Some studies also track corneal curvature and other eye shape parameters
- Data collection happens under controlled conditions to minimize measurement error
Children in Stellest trials typically visit the research clinic every six months. At each visit, technicians measure refraction and axial length, check visual acuity, and examine eye health. This regular monitoring lets researchers detect trends early. In everyday practice, we may schedule visits every three to six months, especially early in treatment or when progression is rapid, then every six months once the response is stable.
The published protocols also include safety checks at each visit. Researchers document any complaints, changes in comfort, or signs of complications. These detailed follow-ups provide the safety data that inform our clinical recommendations today.
Families enrolled in Stellest studies commit to wearing the assigned glasses every day and attending all scheduled visits. Children receive comprehensive eye exams and contribute to scientific knowledge. Parents complete questionnaires about their child's activities, symptoms, and satisfaction.
Trial participants often report feeling proud to help future children. However, they must accept the possibility of being assigned to the control group and receiving standard lenses. This trade-off is central to generating trustworthy evidence that benefits everyone in the long run.
Safety and Side Effects Reported in Studies
Published safety analyses show that most children adapt to Stellest lenses within a few days to two weeks. Some report initial awareness of peripheral blur or slight distortion, which is expected given the lens design. These sensations typically fade as the visual system adjusts.
Researchers track adaptation by asking children and parents to rate comfort and clarity at each visit. The majority of participants in trials report no ongoing discomfort after the initial period. We prepare families for this adjustment phase so it does not cause unnecessary worry.
Studies measure quality of life using validated questionnaires that ask about daily activities, school performance, and sports participation. Children wearing Stellest report similar or better quality of life compared to those in standard glasses. No major limitations in activities have emerged in published data.
- Reading and near-work tasks show no clinically meaningful difference in comfort scores
- Distance vision clarity is generally comparable to standard lenses once adapted, though some children notice mild peripheral blur or visual artifacts early on
- Outdoor play and sports participation remain unaffected according to parent reports
- Overall satisfaction ratings are favorable in the published trials
In published studies, serious device-related adverse events have not been reported, and most issues are mild and related to adaptation, such as blur, visual discomfort, or headaches. As with any spectacles, routine safety and fit checks are still important. Researchers document every safety concern, even those unrelated to the lenses. The few significant events reported are generally common childhood eye issues that would occur with any glasses.
Trials have not attributed serious long-term vision changes directly to Stellest lens wear. This favorable safety profile supports our recommendations, though we still monitor every child closely to catch any individual reactions early. Plausible issues that warrant evaluation include persistent headaches, ongoing blur after the adaptation period, dizziness, new double vision, or discomfort that does not resolve.
Some participants drop out of studies for reasons unrelated to the lenses, such as moving away or losing interest in research visits. Among those who discontinue due to lens-related factors, discomfort or dissatisfaction with vision quality are the most common reasons. These cases represent a small minority of enrolled children.
Published discontinuation rates help us understand real-world adherence. Most children continue wearing Stellest successfully throughout the trial period. When we prescribe these lenses, we discuss what to expect and how to troubleshoot issues before they lead to stopping treatment.
Although Stellest lenses are safe for most children, certain symptoms require prompt evaluation. Contact our office right away if your child experiences any of the following while wearing these or any glasses.
- Sudden decrease in vision in one or both eyes
- Eye pain, significant light sensitivity, or redness that does not improve quickly
- New double vision that persists or worsens
- Flashes of light, new floaters, or a curtain-like shadow in the visual field
- Eye injury, broken lenses causing facial or eye trauma, or any direct impact to the eye
- Severe headaches accompanied by visual symptoms such as blind spots or distortion
What the Evidence Shows About Candidacy
Research identifies several factors that predict faster myopia worsening. Children with two nearsighted parents tend to progress more quickly than those with one or no myopic parents. Younger age at myopia onset also correlates with more total progression over time.
Published studies also link rapid progression to less time outdoors and more intensive near work. These risk factors help us identify which children stand to benefit most from Stellest. If your child has multiple risk factors, we may recommend starting myopia control sooner rather than later.
Most Stellest trials include children aged eight to twelve with myopia ranging from mild to moderate. Prescriptions in published studies typically fall between about negative one and negative five diopters at enrollment. Children within these ranges form the core evidence base.
- Very young children under age eight have limited published data on Stellest
- Teenagers over age thirteen appear in some trials but are underrepresented
- Children with very high myopia at the start may respond differently than those in the studies
- We consider individual factors when recommending Stellest outside the most-studied ranges
Published literature highlights certain patterns that signal a need for intervention. A child whose prescription changes by more than half a diopter in six months is progressing rapidly. Similarly, axial length increases greater than certain thresholds indicate aggressive myopia.
We use these research-based benchmarks during your child's exams. If we detect warning signs, we discuss Stellest and other myopia control options more urgently. Early action based on published evidence can make a meaningful difference over your child's growing years.
Research consensus favors starting myopia control often when myopia is diagnosed, especially in younger children or those with high-risk features, and when progression is documented or anticipated. Waiting until myopia is advanced means missing opportunities to slow growth. Published guidelines suggest considering intervention as soon as a pattern of worsening becomes clear or risk factors indicate likely progression.
For Stellest specifically, trials enroll children who are progressing or at high risk. We apply these criteria in practice, and in some cases our clinical judgment supports starting treatment at diagnosis rather than waiting. Starting at the right time maximizes the potential benefit and aligns with what the studies tell us works best.
Applying Published Research to Your Child's Care
We review the published trials to understand average outcomes, but every child is unique. Statistical significance in a study does not guarantee your child will respond exactly as the group did. We use research as a guide while tailoring recommendations to your family's situation.
When multiple studies show consistent findings, our confidence grows. For Stellest, the body of evidence supports efficacy and safety in the studied age and prescription ranges. We explain both what the research shows and where questions remain, so you can weigh the decision with full information.
Published trial protocols call for measurements every six months. We often adopt a schedule of every three to six months in our office to track whether Stellest is working as expected for your child. Follow-up every three months may be recommended early in treatment or when progression is rapid, then every six months once the response is stable. Regular monitoring lets us detect any unusual progression early and adjust the plan if needed.
- We measure prescription and axial length at each myopia control visit
- Comparing your child's data to research benchmarks helps us assess response
- If progression continues faster than expected, we discuss additional or alternative strategies
- Consistent follow-up is key to delivering the outcomes seen in published studies
Research supports spending more time outdoors as a way to reduce myopia risk. Some families ask whether combining Stellest with increased outdoor play offers extra benefit. While studies have not tested every possible combination, there is good reason to believe multiple healthy habits work together.
We encourage outdoor time, good lighting for reading, and taking breaks during prolonged near work, even when your child wears Stellest. These lifestyle measures are safe, cost nothing, and align with published guidance on myopia prevention. A comprehensive approach may yield the best long-term results.
In trials, children return for exams, measurements, and lens checks every six months. We follow a similar model in routine practice, scheduling regular visits to ensure the lenses fit well and your child's eyes remain healthy. Each visit includes vision testing and a review of any concerns.
Published protocols also emphasize adherence monitoring. We ask how many hours per day your child wears the lenses and troubleshoot any barriers to full-time use. Matching the research standards in real-world care helps your child achieve outcomes similar to those reported in the literature.
Frequently Asked Questions
Several myopia control interventions have peer-reviewed evidence. Orthokeratology trials often include similar age groups and show comparable slowing effects. Atropine eye drop research spans a range of concentrations and protocols, with varying efficacy and side effects like light sensitivity or near blur. Soft multifocal contact lenses also have strong published support. Some families and doctors discuss combination therapy, though evidence for combining treatments is still evolving. Each option has trade-offs in convenience, infection risk for contact-based options, medication side effects, lifestyle burden, and monitoring intensity, so we review all the evidence to find the best fit for your child.
Clinical trials require families to commit to full-time wear and regular visits, which may differ from typical glasses use. However, studies that gather wear-time data show that children in trials do wear the lenses during normal school and play activities. The results reflect real kids in real settings, though highly motivated families may achieve slightly better adherence than the general population.
Published research has not yet followed children into adulthood to confirm long-term eye health benefits, though the mechanism of slowing axial growth is thought to reduce risk of complications. We also lack large trials in very young children or those with extremely high myopia at the start. Questions about what happens after stopping treatment, including whether progression rebounds, need more data. Ongoing studies aim to fill these gaps, and we stay updated as new papers appear.
The longest published follow-up periods extend to about three years. Additional data may emerge as trials continue and researchers publish extended results. Three years is enough to show sustained efficacy and safety, but longer observations would strengthen our understanding of durability and whether benefits persist after children stop wearing the lenses.
Most trials enroll children across a range from low to moderate myopia, and subgroup analyses suggest benefit even in those starting with higher prescriptions. However, children with very high myopia are underrepresented, so we interpret results cautiously in those cases. We consider the available evidence alongside your child's specific needs when making recommendations for moderate to high myopia.
Getting Help for Peer-Reviewed Publications on Stellest
Our eye doctors stay current with the latest published research on Stellest and other myopia control treatments. During your visit, we can discuss specific study findings and how they apply to your child's vision needs. We are here to translate the science into clear, actionable advice that supports your family's decision-making.